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CHLORIN e6 COMBINED WITH ALBUMIN NANOPARTICLES 
AS A POTENTIAL COMPOSITE PHOTOSENSITIZER 
FOR PHOTODYNAMIC THERAPY OF TUMORS
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Aim: To synthesize and to study for photodynamic activity a composite photosensitizer consisting of chlorin e6 and human serum 
albumin nanoparticles (HSA NPs). Materials and Methods: Starting from sorption-purified HSA, the albumin nanoparticles with 
a different degree of lysine residues cross-linking (10; 20; 40, and 100%) were obtained by the coacervation method. The HSA 
NPs were used for synthesis of nanocomposites with chlorin e6 and fluorescein isothiocyanate (FITC)-labled preparations. Ma-
lignant lymphocytes of the MT-4 (human T-cell leukemia) line and normal lymphocytes of healthy donors served as cell targets. 
For photodynamic treatment, a semiconductor laser was exploited as a light source, and cell viability was assessed by MTT or try-
pan blue dye exclusion tests. For cell imaging and HSA NPs visualization, the fluorescence microscopy and transmission electron 
microscopy were applied, respectively. C57Bl/6 mice were used in animal experiments. Results: The absorption and fluorescence 
spectra of chlorin e6-HSA NPs composites were characterized, and by the electron microscopy investigation the size of NPs 
(nanospheres) was estimated: 100–120 nm. FITC-labled albumin preparations allowed to establish that HSA NPs have much 
higher exposition and concentration dependent affinity to malignant cell surface than initial HSA. In experiments with MT-4 cells 
on PDT activity of chlorin e6-HSA NPs, the nanocomposite effectiveness elevated along with increasing percentage of cross-linked 
aminoacid residues, and for the nanocomposite with 100% of albumin cross-linking it exceeded the activity of free chlorin e6. 
In contrast to malignant cells, the complexation of chlorin e6 with HSA NPs decreased its photodynamic effect on normal human 
lymphocytes. Intravenous introduction of the chlorin e6-HSA NPs composite to mice showed prolonged circulation of the nano-
composite in blood in comparison with free PS. Conclusion: Promising results obtained with chlorin e6-HSA NPs composites 
warrant conduction of full-fledged PDT studies in vivo using the nanocomposites as photosensitizers.
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Photodynamic therapy (PDT) of tumors is a modern 
low-traumatic method for oncological patients’ treat-
ment that is winning ever-growing recognition due 
to the absence of serious complications, comparative 
selectivity of antitumor action and moderate cost. Active 
researches are conducted to raise the method selecti-
vity and to expand the sphere of its clinical applications. 
A promising approach to the problem of improving con-
ventional PDT potency consists in designing efficient 
carrier systems for a photosensitizing drug used [1, 2]. 
One way to attain that is to employ as photosensitizer 
(PS) carriers certain non-toxic biocompatible polymers 
(e.g., polyethylene glycol, polyvinylpyrrolidone) which 
are able to extend the PS circulation time and to increase 
its accumulation in tumor tissues due to enhanced 
permeation and retention (EPR) phenomenon [3, 4]. 
Another possibility is based on application of composite 
PSs comprising molecules which have high and/or se-
lective affinity to tumor tissues (transferrin, folic acid, 
specific antibodies) and provide for targeted PS trans-
portation to the tumor [5]. In this context, it seems 
tempting to test as PS carriers the substances which 
are potentially capable of both mechanisms mentioned. 
A serum albumin may be considered one suitable can-
didate for the role. Being a dominant protein of human 
blood plasma, it is biodegradable, non-antigenic and 
functionates in particular as a major natural porphyrine 
carrier in the body [6]. Most important, many tumor cells 
likely have on their surface a larger number of serum 
albumin receptors, in comparison with normal cells [7]. 
However, in its native form serum albumin does not fit 
to serve as a drug transporter and has to be cross-linked 
or stabilized using various known methods. Numerous 
experiments on delivery of diverse drugs with the help 
of modified serum albumin were conducted starting 
from 1970s [8].
PDT studies in which cross-linked human serum 
albumin was used as a vehicle for PS transportation 
were presented in a series of publications by B. Roeder 
and collaborators [9–12]. The studied PSs included 
pheophorbide and Foscan.
In this work we set the task to prepare and to exa-
mine for the photodynamic activity a nanocomposite 
PS that was not characterized earlier: the cross-linked 
human serum albumin (HSA) bearing Photolon — 
a PS approved for PDT applications in Ukraine.
MATERIALS AND METHODS
Preparation of albumin nanoparticles. For our 
experiments we used protein nanospheres obtained 
by coacervation method [13] from HSA deliganded 
with hemosorbents. Albumin nanoparticles (HSA NPs) 
were treated with different amounts of cross-linking 
agent glutaraldehyde to obtain preparations with vari-
ous degrees of cross-linked lysine residues (20; 40, 
and 100%).
HSA NP conjugation with fluorescein isothio-
cyanate. HSA and HSA NPs were dissolved, dialyzed 
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against bicarbonate buffer and lyophilized. Lyophili sates 
were dissolved in bicarbonate buffer to the concentra-
tion of 8 mg/ml. Solutions were dialyzed overnight. 
Fluorescein isothiocyanate (FITC) in dimethylsulfoxide 
was added to HSA or HSA NP solutions and stirred for 
60 min at 37 °C. To remove unbound dye, solutions 
were twice dialyzed overnight. All manipulations were 
performed in a dark room. The efficiency of conjugation 
was analyzed using fluorescence spectroscopy.
Nanocomposite PS preparation. Photolon (mo-
lecular complex of chlorin e6 sodium salt and polyvi-
nylpirrolidone 1:1) was purchased from “Belmedpre-
paraty” (Belarus). It was dissolved in Hanks solution 
(Sigma-Aldrich, USA) and mixed with HSA NPs. 
Because chlorin e6 is unstable in water solutions, 
PS and its nanocomposite solutions were prepared 
immediately before each experiment.
Cell line and cell culture. The MT-4 (human  T-cell 
leukemia) cell line was obtained from the culture bank 
of R.E. Kavetsky Institute for Experimental Patho-
logy, Oncology and Radiobiology National Academy 
of Sciences of Ukraine. Cells in RPMI-1640 medium 
(Biowest, France) containing 10% fetal bovine serum 
(Biowest, France) were maintained in humidified air 
at 37 °C with 5% carbon dioxide. Normal lymphocytes 
were isolated from peripheral blood of healthy donors 
by routine gradient-density method.
Cell survival assay. For PDT tests, cell suspen-
sions (0.5•106 per ml) in Hanks balanced salt solution 
were prepared from MT-4 leukemic cells in a log phase 
of growth, or from normal limphocytes. After 1.5 h of in-
cubation (37 °C) in Hanks solution with chlorin e6 alone 
or with HSA NP-chlorin e6 nanocomposite (employing 
the same PS concentrations as for chlorin e6 alone), 
the cells were washed twice with a 10-fold volume 
of fresh Hanks solution and exposed to the red laser 
light (dose of 1 J/cm2, fluence rate of 1.1 mW/cm2), 
with control “dark” samples treated without irradia-
tion. Then cells were transferred to culture medium. 
Cell viability was assessed using MTT test or trypan 
blue dye exclusion test after 18 hours of postincubation. 
3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bro-
mide for MTT test was obtained from Sigma-Aldrich (USA).
Photoirradiation procedure. For irradiation 
of cells, preincubated with photosensitizing agents, 
the semiconductor laser (Fotonica Plus, Ukraine) with 
emission wavelength of 658 nm was used. Light doses 
were determined using an Ophir Nova II laser Power/
Energy Meter (Ophir Optronics, Israel).
Cells fluorescence microscopy. The MT-4 cells 
were seeded in incubation medium (RPMI 1640 with 
10% fetal bovine serum) at 1.5•105 cells/well in a 96-well 
plates. HSA-NPs-FITC or HSA-FITC was added to cells 
at concentrations of 30 and 300 μg/ml by albumin and 
incubated in humidified atmosphere at 37 °C. Cells 
were then washed three times with Hanks solution, and 
fluorescence of cells was determined by fluorescence 
microscopy (МС 300 FX (Infinitive, Austria)) after 0.5; 
1.5; 4, and 24 h of cell incubation with FITC conjugates.
Determination of chlorin e6 and its nanocom-
posite clearance from the blood. The kinetics 
of PS and its composite with HSA-NPs elimination from 
the bloodstream of C57BL/6 mice (age — 2–2.5 months, 
weight — 19–20 g) was determined 15 min, 1 h, 3 h and 
24 h after photosensitizing agents administration in the 
animal tail vein. The concentration of chlorin e6 intro-
duced with the PS and its nanocomposite was the same 
(2.5 mg/kg). Chlorin e6 concentration in blood plasma 
was determined by fluorescence at a wavelength 
of 660–670 nm using fluorospectrometer NanoDrop 
ND3300 (NanoDrop, USA). The use of experimental 
animals have been performed in accordance with the 
international ethical standards.
Statistical analysis. To examine the differences 
between groups One-way ANOVA test was performed 
using OriginLab program. Differences between values 
with p < 0.05 were considered to be significant. The va-
lues were expressed as means ± standard deviation 
(SD). Experimental data were obtained in triplicates.
RESULTS AND DISCUSSION
Physico-chemical characteristics of HSA NPs 
and their composites with chlorin e6. In this study, 
HSA (fraction V, obtained from Sigma, USA) was used 
after its thorough deligandization by sorption as it was 
described earlier [14]. Such purified HSA has many 
vacant binding sites, demonstrating higher values 
of complexation enthalpy with marker substances (so-
dium octanuate, salicylic acid, phenol red, stearic acid) 
in flow isothermal microcalorimetry tests and increased 
binding of warfarin and diazepam — markers of the first 
and second drug binding sites, respectively [15].
HSA NPs were synthesized from the purified al-
bumin using glutaraldehyde as a cross-linking agent 
via the coacervation method [16]. The NP fraction 
yield made 60–70% of total protein. The degree of ly-
sine residues cross-linking (20; 40, and 100%) was 
determined by the amount of glutaraldehyde used, 
with 100% standing for cross-linking of all 49 lysine 
residues in HSA molecules. The electron microscopy 
investigation showed that HSA NPs present a narrow-
dispersed population of nanoparticles with a smooth 
surface and diameter of 100–120 nm (Fig. 1).
Fig. 1. Transmission electron microscopy image of HSA NPs
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The composites, obtained by complexation of HSA 
and HSA NPs with chlorin e6, were characterized 
by UV-Vis spectrometry and fluorescence analysis. 
Fig. 2 shows absorption spectra of chlorin e6 and 
its composites with HSA and HSA NPs, cross-linked 
by 20 and 100%, respectively. It can be seen that 
complexation of the PS with HSA and especially with 
its NPs induces increase of PS red absorption maxima 
and slight bathochromic shift of spectral B bands.
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Fig. 2. Absorption spectra of HSA and HSA NPs composites 
with chlorin e6. Protein to PS w:w ratio is 1:1
Fluorescence spectroscopy (Fig. 3) also demon-
strated the distinct shift of chlorin e6 662 nm band 
to longer wavelengths under complexation with 
albumin preparations, and an augmentation of the 
tendency is evident when HSA NPs were used instead 
of initial albumin. The changes observed may be pre-
sumably explained by appearance of new binding sites 
in cross-linked protein molecules as it was showed 
in some previous studies [13].
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Fig. 3. Fluorescence spectra of chlorin e6 composites with HSA 
and HSA NPs. Protein to PS w:w ratio is 1:1
HSA NPs cytotoxicity and cell interaction. Dark 
cytotoxicity study (without photoirradiation) of the 
HSA-NPs with different aminoacid residues cross-
linking degree (20; 40, and 100%) was conducted 
in parallel on MT-4 malignant cell line and on normal 
human lymphocytes. It showed an absence of HSA-
NPs negative effects on cell viability (data not shown) 
up to the concentration of 1 mg/ml, that was 5 times 
higher than a maximal dose, used in further research.
To analyse HSA NPs interaction with malignant 
cells, the NPs (100% cross-linking) were conjugated 
to FITC, and the conjugate was used for MT-4 cells 
treatment. Fluorescence microscopy of the conjugate-
treated cells revealed that HSA-NPs are significantly 
superior than initial albumin molecules adsorbed 
on the surface of malignant lymphocytes (Fig. 4). 
The accumulation of NPs was time- and concentration-
dependent with the maximum reached after 4 hours 
of cell incubation with 300 μg/ml NPs. Nevertheless, 
aliready in 30 min of incubation the difference between 
the accumulation of HSA and HSA-NPs on cells was 
clearly visible.
Thus, comparative analysis of accumulation ki-
netics of FITC-labeled purified albumin and its nano-
spheres by MT4 cells demonstrated high affinity of the 
NPs to malignant cell membrane.
Photodynamic activity of HSA NPs composites 
with chlorin e6. Photodynamic activity of nanocom-
posites chlorin e6-HSA NPs with different degree of al-
bumin cross-linking was studied in experiments in vitro 
on malignant lymphoid cell line MT-4 and normal 
lymphocytes isolated from the healthy donor blood. 
The data presented in Fig. 5, a, evidence that photo-
dynamic efficiency of nanocomposites elevated along 
with increasing percentage of cross-linked amino acid 
residues in HSA NPs. The photodynamic damage 
of MT-4 cells preincubated with chlorin  e6-HSA NPs 
(100%) was up to 20% higher than in tests with the free 
chlorin e6. At the same time the initial HSA significantly 
reduced photodynamic effects of chlorin e6. It is im-
portant to note that in experiments with normal human 
lymphocytes, unlike malignant lymphoid cells, HSA 
NPs (100%) also reduced the chlorin e6 photodynamic 
activity (Fig. 5, b).
Chlorin e6-HSA NPs circulation in the blood 
of mice. Since in vivo PDT studies with chlorin e6-HSA 
NPs as a PS are planned, the investigation of the nano-
composite elimination from the blood was undertaken. 
The solutions of chlorin e6 and its HSA NPs composite 
with equal content of chlorin e6 were injected into the 
tail vein of C57Bl/6 mice. The chlorin e6 fluorescence 
(λ emission = 670 nm) in the blood samples was estimated 
during 24 h by fluorimetry.
As it can be seen from Fig. 6, in 15 min after the 
nanocomposite chlorin e6-HSA NPs introduction 
to animals about 30% more of it was detected in the 
bloodstream in comparison with the free PS introduc-
tion. In one hour, the difference was still ~ 27%. But 
three hours after the experiment beginning, plasma 
fluorescence intensity decreased by 10 times, and 
the difference between the animal groups was practi-
cally imperceptible. Alter 24 h, PS fluorescence in the 
blood plasma was no longer detectable. Thus, it can 
be concluded that chlorin e6 complexation with HSA 
NPs is capable to prolong the PS blood circulation.
The principal idea of the present study was to syn-
thesize and to test a composite of chlorin e6 with 
albumin nanoparticles which could serve not only 
as PS transporters but also to protect it from protein 
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corona formation in biological environment and from 
fast removal from the blood by the reticuloendothelial 
system. The current strategy of controlled drug deli-
very involves the use of serum albumin as one of the 
main carriers for pharmaceutical preparations [17–19]. 
This protein is highly resistant to a wide range of envi-
ronmental pH (4 to 8), thermally stable (up to 60 °C), 
biodegradable, has low toxicity, low immunogenicity, 
relatively long half-life (19 days), and high affinity 
to tumor cells and inflamed tissues. Additionally, the 
albumin has a unique three-domain structure repre-
sented by multiple active binding sites [20].
Nanoparticles of natural materials such as albumin 
are actively tested not only for transport of thera-
peutic molecules, but also proteins, DNA and oligo-
nucleotides. Abraxane — drug consisting of albumin 
with paclitaxel on its surface, is already introduced 
in clinical practice to treat breast cancer [21, 22]. 
Albumin conjugate with methotrexate (MTX-HSA) 
is also at the stage of clinical trials for kidney can-
cer therapy. HSA-NPs are actively tested as trans-
porters for PSs such as pheophorbide [9], chlorin 
e6 [23], meta-tetra(hydroxyphenyl)chlorin and 
meso-tetra(hydroxyphenyl)porphyrin [12], and NPs 
from bovine serum albumin — for phthalocyanine 
derivative [24].
The chlorin e6-HSA NPs composite described 
in the present study is only slightly superior to the 
free chlorin e6 by its in vitro photodynamic activity 
and blood-circulation kinetics. However, the results 
of full-fledged PDT experiments in vivo will allow finally 
evaluate the potential of this nanocomposite PS.
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